Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie recently updated its clinical study titled A ...

B/F/TAF shows lower ART switching rates and higher persistence among HIV patients, especially those with mental health or ...

Gilead stock reversed its early losses Friday as analysts noted encouraging indicators for its newly approved HIV prevention ...

More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.

When diagnosed with HIV, the timing of treatment initiation can significantly impact long-term health outcomes and quality of life. Medical experts increasingly advocate for immediate treatment ...

UN World Children's Day on Nov 20 is an annual reminder that every child deserves the chance not just to survive, but to ...

A University of Massachusetts Amherst public health researcher has received four grants totaling $17.9 million from the ...

The American South has the highest HIV rates in the country, accounting for more than half of new HIV diagnoses nationwide in ...

People living with HIV who smoke are currently more likely to die from lung cancer than from HIV-related causes. Two cancer ...